A higher tumor content of CD3+ T cells [3] or CD8+ cytotoxic T cells [4] in late stage tumors is associated with a better prognosis for ovarian cancer patients while a higher relative content of T regulatory cells is associated with a poorer prognosis [5], suggesting the number and types of immune cells are important for clinical outcomes. The gene discussed is CD8A; the disease is neoplasm.